L ipoprotein(a) [Lp(a)] is an independent and likely causal risk factor for cardiovascular disease and calcific aortic valve stenosis. [1] [2] [3] Lp(a) plasma levels are primarily (≈90%) determined by variations in the LPA gene locus, 4 including the number of kringle IV 2 repeats and LPA single-nucleotide polymorphisms. In addition, apolipoprotein(a) gene expression can be modulated by interleukin-6 that increases hepatocyte apolipoprotein(a) production and by estrogen and bile acids that decrease production. 5, 6 Clearance mechanisms are not well defined, but the major possibilities include the lowdensity lipoprotein (LDL) receptor (LDLR), scavenger receptor B1, 7 plasminogen receptors, and renal mechanisms.
of APOE genotypes with Lp(a)-cholesterol [Lp(a)-C] and advanced measures of lipoproteins, such as plasma levels of apo B100, LDL-particle number, small, dense LDL, and high-sensitivity C-reactive protein, has not been previously evaluated. In this study, we describe the relationship of APOE genotypes with Lp(a) levels and apoB-related lipoprotein measurements in a large database from a referral laboratory.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Baseline Characteristics
The data are presented by APOE isoform genotype in Table 1 .
The prevalence of APOE traits were ε2: 7.35%, ε3: 77.56%, and ε4: 15.09%. The prevalence of APOE genotypes were ε2/ε2: 0.61%, ε2/ε3: 11.17%, ε2/ε4: 2.3%, ε3/ε3: 60.41%, ε3/ε4: 23.14%, and ε4/ε4: 2.38%. The mean age range was ≈54 to 56, ≈53% of patients were female, and body mass index was ≈30.
Lipid and Lipoprotein Variables
Corresponding mean (SD) Lp(a) levels increased significantly according to APOE genotype ranging from 23.4 mg/dL for ε2/ε2 to 38.5 (44.1) mg/dL for ε4/ε4 (P<0.0001; ANOVA; Table 1 ; Figure 1 ). Median Lp(a) levels also increased by genotype, from 11 mg/dL for ε2/ε2 to 20 mg/dL for ε4/ε4. Along with Lp(a) mass, Lp(a)-C also increased according to APOE genotype. Mean LDL-C also increased by APOE genotype ranging from 49.6 mg/dL for ε2/ε2 to 114.3 mg/dL for ε4/ε4 (P<0.0001; ANOVA). Corresponding mean apoB levels ranged from 56.6 for ε2/ε2 to 101.1 mg/dL for ε4/ε4 (P<0.0001; ANOVA). Striking increases in LDL-particle number and small, dense LDL were also noted according to the genotype, with lowest values in ε2/ε2 to highest values in ε4/ε4. In contrast, median triglyceride levels were inversely associated with APOE genotype from 140 to 109 mg/dL for ε4/ε4 (P<0.0001; ANOVA). A similar but modest inverse association was noted with high-density lipoprotein-cholesterol (P<0.0001; ANOVA). Finally, high-sensitivity C-reactive protein was also inversely associated with APOE genotype, with highest values in highest values in ε2/ε2 to lowest values in ε4/ε4 (Table 1) . The data are provided as mean (SD) or median (interquartile range). LDL-C corr is LDL-C corrected for Lp(a)-C content and is derived as LDL-C minus (Lp(a) mass×0.3). HDL-C indicates high-density lipoprotein-cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL, low-density cholesterol; LDL-C, low-density lipoprotein-cholesterol; Lp(a), lipoprotein(a); and Lp(a)-C, lipoprotein(a)-cholesterol.
For the patients with ε2/ε2 genotype, a portion of which can have elevated triglycerides when a secondary stimulus accelerates VLDL production, additional analyses were performed. Out of 2445 patients with ε2/ε2 genotype, there were 1205, 782, and 93 patients with triglyceride levels ≥150, ≥200, and ≥500 mg/dL, respectively. Patients with different cutoffs of triglycerides did not have significantly different Lp(a) mean (SD) levels: triglycerides <150 versus ≥150 mg/dL (23.1 [28.5] Figure 1 shows a graphical representation of some of the key relationships.
Correlations Among Variables
Using a validated Lp(a)-C assay, 16 the Spearman correlation between Lp(a) mass and Lp(a)-C was r 2 =0.79 (P<0.001) and between Lp(a) mass and LDL-C r 2 =0.008 (P<0.001; Figure 2 ). All other correlations of Lp(a) mass with variables in Table 1 had r <0.10, but because of the large numbers all were statistically significant with P<0.001 (data not shown). Lp(a)-C also had a weak correlation with LDL-C (r Table 1 had r <0.10, but because of the large numbers all were statistically significant with P<0.001 (data not shown).
Relationship of APOE Isoforms to LDL-C ≥190 mg/dL and LDL-C ≥250 mg/dL
Because LDLR mutation status was not available, we used LDL-C ≥190 and ≥250 mg/dL as potential surrogates for LDLR deficiency to derive insights into the potential role of the LDLR vis-à-vis APOE genotypes and Lp(a) catabolism. The analysis showed that compared with patients with LDL-C <190 or <250 mg/dL, respectively, patients with LDL-C ≥190 mg/dL (mean When analyzed by APOE isoform status and LDL-C cutoffs, the lowest Lp(a) levels were present in ε2 genotypes with concomitant low LDL-C (Table 2 ). In contrast, ε2 genotypes with concomitant high LDL-C had the highest Lp(a) levels. The differences in Lp(a) levels according to APOE genotypes and normal or elevated LDL-C were greatest in ε2 genotypes and smallest in ε4 genotypes. For example, in individuals with ε2/ε3 genotype (there was only 1 ε2/ε2 individual with LDL ≥190, so this genotype could not be examined), Lp(a) levels were 31.2 (37.9) for LDL-C <190 mg/dL and 63.3 (57.5) for LDL ≥190 mg/dL (P<0.001). In contrast, for ε4/ε4, Lp(a) levels were 38.1 (43.8) mg/dL for LDL-C <190 mg/dL and 50.2 (52.1) for LDL ≥190 mg/dL (P<0.001).
Discussion
The current data document that APOE isoforms strongly influence Lp(a) mass levels, with a 65% increase in ε4/ε4 compared with ε2/ε2 genotypes. Consistent with this, Lp(a)-C levels, determined with an assay that strongly reflects Lp(a) mass, 16 also increased according to APOE genotypes. In addition, a variety of measures of lipoprotein particle number, including apoB levels, LDL-particle number, and small, dense LDL had similar statistically significant associations. Finally, it was documented that concomitantly highly elevated LDL-C, a potential surrogate for LDLR deficiency, also influenced Lp(a) levels overall with higher levels in subjects with elevated LDL, as shown previously with a gene-dose relationship in subjects with homozygous and heterozygous familial hypercholesterolemia. 17, 18 This relationship was particularly accentuated in patients with ε2/ε2 genotypes that have the lowest affinity for the LDLR and LRP-1. Because apoE proteins are not thought to directly affect hepatocyte synthesis of apolipoprotein(a) or impact Lp(a) assembly or secretion, it suggests that Lp(a) catabolism is influenced by apoE affinities for lipoprotein receptor clearance pathways such as LDLR and LRP-1. These data further suggest a competition for such receptors by apoE and Lp(a) that affect circulating Lp(a) levels. It may also explain the weak to modest inverse correlation noted with Lp(a) and triglycerides in this study and several other studies, with higher Lp(a) levels being associated with lower triglyceride levels. 19, 20 Figure 3 represents a hypothetical construct of these relationships. ApoE isoforms at the protein level are characterized by differences in 1 or 2 amino acids: ɛ3 has Cys-112 and Arg-158, ɛ4 has Arg-112 and Arg-158, and ɛ2 has Cys-112 and Cys-158. The LDLR binding activity for ɛ3 and ɛ4 is reported to be normal, but ɛ2 has <2% of normal LDLR binding activity and is associated with recessive inheritance and low penetrance (10%). 12, 21, 22 The binding of apoE proteins to LRP-1 has not been well studied, but ligand blotting experiments suggest that lipid-bound apoE2 has 30% to 50% of normal LRP-1 binding activity. 23 The defective binding of apoE2 to the LDLR results in clinical expression of type III hyperlipoproteinemia in the presence of another factor (diabetes mellitus, obesity, hypothyroidism, or estrogen deficiency) that overwhelms the capacity of apoE2 to mediate remnant lipoprotein clearance because of increases in VLDL production or reduced LDLR expression. These amino acid differences also result in different affinities for triglyceride-rich lipoproteins that lead to different effects on remodeling of VLDL to LDL and in receptor-mediated remnant clearance. 12, [24] [25] [26] [27] [28] [29] [30] The apoE4 protein is reported to prefer large, triglyceride-rich lipoproteins (VLDL and chylomicrons), whereas apoE3 and apoE2 proteins preferentially bind to small spherical high-density lipoprotein particles. 31, 32 In that regard, the apoE4 isoform is associated with the lowest triglyceride levels but higher LDL-C. It is presumed that enrichment of apoE4 on VLDL accelerates its clearance from the circulation by liver LDLR, LRP-1, and syndecan-1 consequently downregulating hepatic LDLR expression. In addition, the enrichment of apoE4 on VLDL can outcompete LDL binding to LDLR because of the 20-fold greater affinity of apoE3 and apoE4 for LDLR compared with apo B100, further increasing circulating LDL-C. 9, 33 Controversy exists whether the LDLR is involved in clearance of Lp(a) and data from cell culture, animal and human studies have given conflicting results. Initial studies revealed that the clearance rate of Lp(a) was similar when radiolabeled Lp(a) is injected in small numbers of human with homozygous or heterozygous familial hypercholesterolemia or mice with or without intact LDLRs. 15, 34 In addition, statins increase LDLR density, but a seemingly paradoxical effect of statin treatment on Lp(a) levels occurs, and statins do not lower plasma Lp(a) levels. In fact, a recent analysis of 3896 patients on multiple statins and different doses of statins modestly raised mean Lp(a) levels by a mean of 11% and ≤50% in some studies. 35 These studies argue against a major role of the LDLR in Lp(a) clearance.
However, Lp(a) was shown to compete for LDL for binding to human LDLR in intact fibroblasts and that overexpression of the human LDLR in mice led to faster clearance of Lp(a). 36 In addition, patients with familial hypercholesterolemia with abnormalities in the LDLR not only have higher LDL-C but also 1.5 to 2× higher Lp(a) in a gene-dose relationship compared with their unaffected siblings. 17, 18 These studies argue for a role of the LDLR in clearance of Lp(a). More recent cell culture studies have also had conflicting results, with 1 study showing that Lp(a) catabolism in human hepatoma cell lines and primary fibroblasts is inhibited by PCSK9 via the LDLR, which mediated the effects of PCSK9 on Lp(a) internalization. 8 However, another study suggests that the LDLR plays no role, but that PCSK9 may potentiate Lp(a) secretion, a pathway inhibited by PCSK9 antibodies. 37 The current data also favor that the LDLR is involved in clearing Lp(a), but that this is also influenced by the underlying APOE genotype that also competes for the same receptor. However, it is not possible to quantify this effect or the effect of non-LDLR pathways, such as plasminogen and SRB-1 (scaveger receptor B) receptors. 7, 8 The apolipoprotein(a) molecule is large with molecular mass ≈200 to 900 KD and often larger than apo B100. It is covalently linked by a disulfide bond at cysteine number 4326 on apoB which is near the apoB docking site that binds to the LDLR. Thus, the apolipoprotein(a) of Lp(a) may cause the The data are presented as mean (SD) or median (interquartile range). *For Lp(a)-C, there were 667 patients in ε2/ε2, 84 in ε2/ε3, 62 in ε2/ε4, 86 853 in ε3/ε3, 34 995 in ε3/ε4, and 142 in ε4/ε4 groups. HDL-C indicates high-density lipoprotein; LDL-C corr, low-density lipoprotein-cholesterol corrected; LDL-C, low-density lipoproteincholesterol; Lp(a), lipoprotein(a); Lp(a)-C, lipoprotein(a)-cholesterol; and TG, triglyceride. 
apoB of Lp(a) to be sterically hindered in its interaction with the LDLR and thus slow Lp(a)'s clearance. This is supported by the fact that Lp(a) has slower clearance rate than LDL, approximately a day longer with a fractional catabolic rate of 0.22 pools per day versus fractional catabolic rate of 0.37 pools per day for LDL, 38, 39 and that when apolipoprotein(a) synthesis is inhibited by antisense oligonucleotides, LDL-C is significantly reduced. The effect of the apolipoprotein(a) antisense oligonucleotides on LDL is independent of effects on apoB synthesis and LDL production, 40, 41 which is in agreement with the different metabolic production routes for Lp(a) and LDL production. 42 This study also demonstrates that LDL-C levels and apo B100 variables distribute in the same direction as Lp(a) mass and Lp(a)-C. Despite this, there is almost negligible correlation between Lp(a) and LDL-C or apoB because of different genetic influences in production of each. Despite the fact that Lp(a), unlike LDL, is not derived from a VLDL precursor, the mechanisms associated with elevation of each may be similar. One may postulate that when apoE is present on larger chylomicron remnants and VLDL particles, it competes for binding to LDLR and LRP-1. When there is relatively high affinity for these receptors, such as apoE4 (and apoE3), it leads to higher LDL-C, apoB, and Lp(a). In contrast, when there is lower affinity, such as with apoE2, LDL and Lp(a) particles can clear faster. In addition, the slower conversion of VLDL to LDL with ɛ2 genotype leads to lower LDL levels, which further enhances Lp(a) clearance because of less LDL competition for Lp(a) clearance. The additional increment in circulating Lp(a) levels in ε4/ε4 patients is likely explained by the fact the ε4 partitions preferentially on triglyceride-rich lipoproteins and thus generates a bigger mass of lipoproteins to outcompete Lp(a) binding.
It is also possible that LRP-1 may be responsible for the observed apoE-Lp(a) relationship. The apoE2 isoform has negligible binding to LDLR (<2% compared with ε3). If LDLR was responsible for our observed association, one could expect to see a reduction in plasma Lp(a) and Lp(a)-C levels between ε3/ε3 and ε2/ε2 patients greater than the observed 27% and 14%. In contrast to LDL and apoB, both cleared by LDLR, are 50% to 55% lower in ε2/ε2 patients. Binding of the ε2 isoform to LRP-1 is only reduced by 50% to 70% and can possibly explain the less drastic reduction in Lp(a) levels in ε2/ε2 patients compared with LDL and apoB. The underlying mechanisms of elevation of Lp(a) in different APOE isoforms are evidently more complex and whether LDLR and LRP-1 receptors pay a role in this relationship needs to be determined in experimental studies.
Limitations of this study are the lack of data on race and lipid-modifying therapies. This study provides a rationale to study the role of apoE in explaining differences in Lp(a) and in therapeutic interventions such as with PCSK9 inhibitors and antisense oligonucleotides to Lp(a) lowering. 40, 43 Sources of Funding P.L.S.M. Gordts is supported by the American Heart Association grant 15BGIA25550111. S. Tsimikas is supported by National Institutes of Health grants HL119828, HL055798, HL088093, HL106579, HL078610, and HL124174. 
